InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated:20 April 2023

FORTITUDE-102: This phase Ib/III study is evaluating the safety and effectiveness of targeted therapy (bemarituzumab), compared to a placebo, when combined with chemotherapy (mFOLFOX6) and immunotherapy (nivolumab) in people with previously untreated, advanced stomach and gastro-oesophageal junction cancer with FGFR2b overexpressionA Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

Clinical summary

Summary

This study is being conducted in two parts. Part 1 (the phase Ib part) is evaluating how safe and tolerable bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab are when combined. Participants in this part will receive bemarituzumab at different doses (via intravenous [IV] infusion), with mFOLFOX6 (administered via IV) and nivolumab (via IV) to determine the recommended phase 3 dose (RP3D). Part 2 of the study (the Phase III section) is evaluating the efficacy of bemarituzumab plus mFOLFOX6 and nivolumab to placebo plus mFOLFOX6 and nivolumab. Eligible participants will be randomly allocated to either the experimental arm or placebo control arm. In the Experimental Arm, participants will receive bemarituzumab (administered via IV at the RP3D), in combination with mFOLFOX6 (via IV) and nivolumab (via IV). In the Placebo Comparator arm, participants will receive a placebo (via IV) in combination with mFOLFOX6 (via IV) and nivolumab (via IV).

Age

People18 - 100

Phase

III

Trial Acronym

FORTITUDE-102

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor

AMGEN

Scientific Title

A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

Eligibility

Inclusion

  • You have certain types of non-cancer medical conditions.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Exclusion

  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more